Xenetic Biosciences (XBIO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.99, -1.00% vs the prior close of $2.01.
- Volume 17.47K shares, 0.2x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
XBIO dips 1.0% to $1.99, a 52-week low, 5 down days in a row. Closed at $1.99, -1.00% vs the prior close of $2.01. Day range $1.92–$2.00, opened at $1.98.
XBIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — XBIO dips 1.0% to $1.99, a 52-week low, 5 down days in a row
- Closed at $1.99, -1.00% vs the prior close of $2.01. Day range $1.92–$2.00, opened at $1.98.
- Volume was 17.47K shares, 0.2x its 50-day average of 103.57K — lighter than usual.
- Price is -36.0% vs its 50-day average ($3.11) and -30.3% vs its 200-day average ($2.85).
- 52-week range $1.87–$4.94; today's close sits at 4% of that range, 59.7% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — XBIO slides 4.3% to $2.01, a 52-week low, 4 down days in a row
- Closed at $2.01, -4.29% vs the prior close of $2.10. Day range $1.88–$2.10, opened at $2.09.
- Volume was 51.40K shares, 0.5x its 50-day average of 103.86K — lighter than usual.
- Price is -35.7% vs its 50-day average ($3.13) and -29.6% vs its 200-day average ($2.86).
- 52-week range $1.87–$5.28; today's close sits at 4% of that range, 61.9% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — XBIO ends flat (+0.0%) to $2.10, 3 down days in a row
- Closed at $2.10, +0.00% vs the prior close of $2.10. Day range $2.07–$2.14, opened at $2.07.
- Volume was 12.60K shares, 0.1x its 50-day average of 104.97K — lighter than usual.
- Price is -33.3% vs its 50-day average ($3.15) and -26.5% vs its 200-day average ($2.86).
- 52-week range $1.87–$5.90; today's close sits at 6% of that range, 64.4% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — XBIO dips 0.9% to $2.10, a 6-month low
- Closed at $2.10, -0.94% vs the prior close of $2.12. Day range $2.04–$2.17, opened at $2.14.
- Volume was 33.90K shares, 0.3x its 50-day average of 106.87K — lighter than usual.
- Price is -33.6% vs its 50-day average ($3.16) and -26.4% vs its 200-day average ($2.86).
- 52-week range $1.87–$6.51; today's close sits at 5% of that range, 67.8% below the 52-week high.
Oct 12, 2026 — XBIO dips 0.5% to $2.12
- Closed at $2.12, -0.47% vs the prior close of $2.13. Day range $2.11–$2.27, opened at $2.14.
- Volume was 8.50K shares, 0.1x its 50-day average of 106.87K — lighter than usual.
- Price is -33.2% vs its 50-day average ($3.17) and -25.8% vs its 200-day average ($2.86).
- 52-week range $1.87–$8.87; today's close sits at 4% of that range, 76.1% below the 52-week high.
Oct 9, 2026 — XBIO rises 0.5% to $2.13
- Closed at $2.13, +0.47% vs the prior close of $2.12. Day range $2.13–$2.23, opened at $2.19.
- Volume was 10.20K shares, 0.1x its 50-day average of 106.87K — lighter than usual.
- Price is -33.0% vs its 50-day average ($3.18) and -25.4% vs its 200-day average ($2.86).
- 52-week range $1.87–$10.24; today's close sits at 3% of that range, 79.2% below the 52-week high.
Oct 8, 2026 — XBIO slides 4.1% to $2.12
- Closed at $2.12, -4.07% vs the prior close of $2.21. Day range $2.10–$2.18, opened at $2.18.
- Volume was 13.60K shares, 0.1x its 50-day average of 106.65K — lighter than usual.
- Price is -33.5% vs its 50-day average ($3.19) and -25.8% vs its 200-day average ($2.86).
- 52-week range $1.87–$13.93; today's close sits at 2% of that range, 84.8% below the 52-week high.
Oct 7, 2026 — XBIO jumps 4.2% to $2.21
- Closed at $2.21, +4.25% vs the prior close of $2.12. Day range $2.11–$2.21, opened at $2.11.
- Volume was 15.60K shares, 0.1x its 50-day average of 106.71K — lighter than usual.
- Price is -30.9% vs its 50-day average ($3.20) and -22.6% vs its 200-day average ($2.86).
- 52-week range $1.87–$13.93; today's close sits at 3% of that range, 84.1% below the 52-week high.
Oct 6, 2026 — XBIO slides 3.6% to $2.12, a 6-month low, 4 down days in a row
- Closed at $2.12, -3.64% vs the prior close of $2.20. Day range $2.10–$2.34, opened at $2.19.
- Volume was 14.70K shares, 0.1x its 50-day average of 106.48K — lighter than usual.
- Price is -33.8% vs its 50-day average ($3.20) and -25.8% vs its 200-day average ($2.86).
- 52-week range $1.87–$13.93; today's close sits at 2% of that range, 84.8% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — XBIO dips 1.8% to $2.20, 3 down days in a row
- Closed at $2.20, -1.79% vs the prior close of $2.24. Day range $2.19–$2.29, opened at $2.23.
- Volume was 9.50K shares, 0.1x its 50-day average of 107.42K — lighter than usual.
- Price is -31.5% vs its 50-day average ($3.21) and -23.0% vs its 200-day average ($2.86).
- 52-week range $1.87–$13.93; today's close sits at 3% of that range, 84.2% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — XBIO ends flat (+0.0%) to $2.24
- Closed at $2.24, +0.00% vs the prior close of $2.24. Day range $2.11–$2.33, opened at $2.30.
- Volume was 43.20K shares, 0.4x its 50-day average of 106.99K — lighter than usual.
- Price is -30.4% vs its 50-day average ($3.22) and -21.5% vs its 200-day average ($2.86).
- 52-week range $1.87–$13.93; today's close sits at 3% of that range, 83.9% below the 52-week high.
XBIO latest news & SEC filings
Every SEC filing by or about XBIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 18, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $660.60K (prior year $589.90K) (+12.0% vs Jun 30, 2025)
- Net income: -$929.70K (prior year -$688.70K) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.41 (prior year -$0.45) (loss narrowed vs Jun 30, 2025)
Things to know before you trade XBIO
- Last results release: Aug 7, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 13, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 6, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.08% (largest 14.0%). That is a volatile stock.
- Liquidity: about 41.23K shares (≈$82.06K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.99 vs a range of $1.87–$4.94 (4% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 23, 2026; 8-K Sep 16, 2026; 8-K Aug 7, 2026.
- Share count: 2.34M shares outstanding (Jul 31, 2026), +51.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
XBIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.98 | 2.00 | 1.92 | 1.99 | 17.47K |
| Oct 15, 2026 | 2.09 | 2.10 | 1.88 | 2.01 | 51.40K |
| Oct 14, 2026 | 2.07 | 2.14 | 2.07 | 2.10 | 12.60K |
| Oct 13, 2026 | 2.14 | 2.17 | 2.04 | 2.10 | 33.90K |
| Oct 12, 2026 | 2.14 | 2.27 | 2.11 | 2.12 | 8.50K |
| Oct 9, 2026 | 2.19 | 2.23 | 2.13 | 2.13 | 10.20K |
| Oct 8, 2026 | 2.18 | 2.18 | 2.10 | 2.12 | 13.60K |
| Oct 7, 2026 | 2.11 | 2.21 | 2.11 | 2.21 | 15.60K |
| Oct 6, 2026 | 2.19 | 2.34 | 2.10 | 2.12 | 14.70K |
| Oct 5, 2026 | 2.23 | 2.29 | 2.19 | 2.20 | 9.50K |
| Oct 2, 2026 | 2.30 | 2.33 | 2.11 | 2.24 | 43.20K |
| Oct 1, 2026 | 2.34 | 2.34 | 2.21 | 2.24 | 13.40K |
| Sep 30, 2026 | 2.26 | 2.34 | 2.22 | 2.32 | 30.40K |
| Sep 29, 2026 | 2.34 | 2.35 | 2.25 | 2.26 | 12.30K |
| Sep 28, 2026 | 2.37 | 2.47 | 2.23 | 2.33 | 34.70K |
| Sep 25, 2026 | 2.42 | 2.53 | 2.33 | 2.39 | 50.70K |
| Sep 24, 2026 | 2.56 | 2.56 | 2.28 | 2.47 | 64.00K |
| Sep 23, 2026 | 2.65 | 2.65 | 2.43 | 2.52 | 90.30K |
| Sep 22, 2026 | 2.99 | 2.99 | 2.44 | 2.57 | 152.60K |
| Sep 21, 2026 | 2.81 | 3.10 | 2.80 | 2.99 | 145.60K |
About Xenetic Biosciences
Xenetic Biosciences (XBIO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in FRAMINGHAM, MA. State of incorporation: NV. Fiscal year ends December 31. SEC CIK 1534525.
XBIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Grigory G. Borisenko | Director | Jan 5, 2026 |
| Firdaus J. Dastoor | Director | Jan 5, 2026 |
| Roger D. Kornberg | Director | Jan 5, 2026 |
| Alexey Andreevich Vinogradov | Director | Jan 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James F Parslow | Interim CEO and CFO | Apr 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
XBIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.98M | $-2.68M | -1.58 | $-2.29M |
| Dec 31, 2024 | $2.50M | $-3.96M | -2.57 | $-2.82M |
| Dec 31, 2023 | $2.54M | $-4.13M | -2.71 | $-4.11M |
| Dec 31, 2022 | $1.71M | $-6.55M | -4.61 | $-4.65M |
| Dec 31, 2021 | $1.16M | $-5.65M | -0.55 | $-4.74M |
Latest balance sheet: total assets $6.97M, total liabilities $894.98K, cash $— (as of Jun 30, 2026).
XBIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 7, 2026 | 8-K Item 2.02 (results) | $3.17 |
| May 13, 2026 | 8-K Item 2.02 (results) | $3.18 |
| Mar 13, 2026 | 8-K Item 2.02 (results) | $2.81 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $2.57 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $2.99 |
| May 14, 2025 | 8-K Item 2.02 (results) | $3.12 |
| Mar 19, 2025 | 8-K Item 2.02 (results) | $3.52 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $3.65 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 10, 2024 | 8-K Item 2.02 (results) | — |
| Mar 22, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on XBIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.